A somatic EZH2 mutation in childhood acute myeloid leukemia Although treatment results in childhood acute myeloid leukemia (AML) have improved with the use of risk-directed treatment and improved supportive care, there is still a significant number of patients with unfavorable prognosis. 1 To date, analyses of cytogenetic aberrations provide the most important prognostic information at diagnosis of this heterogeneous disease. Different mutations in several genes have been identified in childhood AML, most commonly NPM1, FLT3-ITD, CEBPA and WT1.
1 Some of these genetic alterations have been associated with treatment outcome and may serve as a basis for improved risk assessment and molecular-based therapies. Recently, mutations in genes that are involved in epigenetic regulation have been described in pediatric AML including TET2, DNMT3A and IDH1/2.
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There is growing evidence that epigenetic deregulation has an important role in the pathogenesis of childhood and adult AML. The most common chromosomal abnormalities found in childhood AML cause chromatin changes through rearrangement of the MLL gene---a histone methyltransferase---to several partner genes. 1 Besides histone modifications, changes in DNA methylation can also be observed. Using large-scale genome-wide DNA methylation profiling, Figueroa et al. 7 recently revealed specific DNA methylation signatures for identification of biologically distinct AML subtypes in adults. Moreover, an AML subset characterized by hypermethylation and silencing of the CEBPA promoter has been shown to cause similar expression profiles as an AML subtype with CEBPA mutations.
EZH2 encodes the catalytic subunit of the polycomb repressive complex 2, a highly conserved histone H3 lysine 27 (H3K27) methyltransferase that influences stem cell renewal by epigenetic repression of genes involved in cell fate decisions. EZH2 is overexpressed in a number of epithelial and hematological malignancies and its overexpression has been associated with poor prognosis in both breast and prostate cancer. 13 In contrast, the EZH2 mutations seen in myeloid disorders are inactivating, a finding that was unexpected but is consistent with models, suggesting that a critical balance of polycomb activity is essential for normal stem cell activity, with either loss or gain of polycomb function being potentially tumorigenic. 14 We sought to determine the frequency and prognostic impact of EZH2 mutations on a well-defined cohort of 75 randomly selected childhood AML patients. Patients' characteristics are provided in Table 1 . Genomic DNA was isolated from bone marrow cells at diagnosis (n ¼ 63) and/or at relapse (n ¼ 15). In three patients, both diagnostic and relapse samples were available. PCRs were performed as described previously using the standard conditions with primers covering all the exons of the EZH2 gene, including its intron --exon boundaries to detect potential splice mutations. 9 Sanger sequencing was performed bidirectionally using an ABI 3500 Genetic Analyzer (Applied Biosystems, Darmstadt, Germany) and analyzed using Mutation Surveyor (SoftGenetics, State College, PA, USA).
We found one EZH2 mutation in a single childhood AML case. The mutation was a homozygous in-frame insertion of 6 bp within EZH2 exon 20 that was confirmed in a second independent analysis. On protein level, the mutation inserts the two amino acids lysine and threonine at position 743 and 744 (SET domain), respectively, resulting in an abnormal EZH2 protein with a length of 753 amino acids. Such an insertion has not been described in the literature so far. Furthermore, the mutation is not listed within the NCBI SNP-Database (dbSNP). Analysis of subsequent remission samples showed an absence of the mutation, indicating that the EZH2 mutation is somatic (Figure 1) .
The patient was a 16-year-old girl harboring AML (FAB type M2) without Auer rods and central nervous system involvement but confirmation of leukemic blasts in bilateral pleural effusions. Initially, bone marrow examination revealed 24% blasts and scattered atypical eosinophils. Flow cytometric analysis was positive for CD 33, CD 65, CD 15 but not for CD 13. Cytogenetic analysis showed the karyotype 45,X,t(8;21)(q22;q22). The patient was subsequently treated within the high-risk group of the German AML-BFM 93 trial as described in detail previously. 15 The patient received an 8-day induction with cytarabine, idarubicin and etoposide (AIE). The bone marrow on day 15 was hypocellular with o5% blasts. The patient suffered from fever in neutropenia, mucositis and a fungal maxillary sinus infection with confirmation of Aspergillus fumigatus that required surgical intervention. After that, the patient received a 6-week consolidation with 6-thioguanine, prednisolone, vincristine, doxorubicin, cytarabine and cyclophosphamide followed by high-dose cytarabine and mitoxantrone. A subsequent bone marrow examination showed continuous complete remission. The patient suffered from repetitive dental infections with the need for surgical treatments. On month 4, the patient suffered from an epileptic seizure that was treated with valproat. The chemotherapy was continued with one intensification cycle of high-dose cytarabine and etoposide (HAE). The patient received a prophylactic cranial irradiation and intrathecal therapy with cytarabine. Allogeneic stem cell transplantation was not performed because of the lack of a HLAidentical sibling donor. A maintenance therapy with 6-thioguanine and cytarabine was given. The patient remained in remission and was discharged from hospital after 8 months of treatment. After 6 months, the patient was hospitalized because of weight loss, thrombocytopenia and hepatosplenomegaly. Repeated bone marrow examinations revealed no evidence for AML relapse. In the following, the patient suffered from a severe aspergillus sepsis and died due to a septic multiple organ failure with bleeding complications.
To our knowledge, this is the first report to describe a somatic EZH2 mutation in pediatric AML. Although EZH2 mutations seem to be rare in childhood AML, our findings indicate that EZH2 mutations might contribute to the disease in specific cases. The incidence of EZH2 mutations in childhood AML needs to be assessed in a larger cohort of patients particularly in children with t(8;21).
